Overview
TNXP market data
Price History
TNXP price chart · 1M
- O
- 13.69
- H
- 14.04
- L
- 13.46
- C
- 13.54
- Vol
- 34,300.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $13.69
- Previous Close
- $13.64
- Day High
- $14.04
- Day Low
- $13.46
- 52 Week High
- $15.81
- 52 Week Low
- $9.44
- 7 Day Return
- +9.37%
- 30 Day Return
- +36.30%
- 90 Day Return
- +9.51%
- 1 Year Return
- +9.15%
- Daily Notional Volume
- $464.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.77 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -839.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.40 – $37.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $214.4M · P/B 0.81 · P/S 12.21.
Company News
8-K filing — Tonix Pharmaceuticals Holding Corp. (TNXP)SEC EDGAR · Aug 18, 2026, 8:00 PM
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M EstimateBenzinga · Aug 10, 2026, 11:01 AM
Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In USBenzinga · Aug 3, 2026, 11:11 AM
Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASMBenzinga · Jul 15, 2026, 1:07 PM
Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027Benzinga · Jul 13, 2026, 11:07 AM
Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6Benzinga · Jun 29, 2026, 11:15 AM
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For ThursdayBenzinga · Jun 25, 2026, 4:25 PM
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For ThursdayBenzinga · Jun 25, 2026, 2:20 PM
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jun 25, 2026, 12:50 PM
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYABenzinga · Jun 8, 2026, 12:45 PM